Cullinan Therapeutics (CGEM) Retained Earnings (2020 - 2026)

Cullinan Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at $127000.0 for Q1 2026.

• In Q1 2026, Retained Earnings rose 100.03% year-over-year to $127000.0; the TTM figure through Mar 2026 stood at $127000.0 (up 100.03% YoY), while the FY2025 annual figure was -$588.1 million, down 59.71% from the prior year.
• Retained Earnings for Q1 2026 stood at $127000.0, up from -$588.1 million in the prior quarter.
• The five-year high for Retained Earnings was $3.9 million in Q2 2022, with the low at -$588.1 million in Q4 2025.
• The 5-year median for Retained Earnings is -$2.6 million (2022), against an average of -$121.6 million.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings surged 3483.48% in 2022, then tumbled 285357.36% in 2024.
• Cullinan Therapeutics' Retained Earnings stood at -$2.6 million in 2022, then jumped by 95.04% to -$129000.0 in 2023, then sank by 285357.36% to -$368.2 million in 2024, then sank by 59.71% to -$588.1 million in 2025, then jumped by 100.02% to $127000.0 in 2026.
• Business Quant data shows CGEM's Retained Earnings at $127000.0 in Q1 2026, -$588.1 million in Q4 2025, and $973000.0 in Q3 2025.